The Medicare GLP-1 Bridge
A Medicare pathway offering a fixed monthly cost for a covered GLP-1 has been widely reported, with clinical eligibility criteria and several exclusions. This page sets out what is reported, and is explicit about what we have been unable to confirm.
Pricing data as of .
Who can use this, and what to watch for
Every point below comes from the same data file that drives the price table, so it cannot drift from the figures on this page.
You cannot use this pathway if
- This program is reported to be for beneficiaries who cannot already get a GLP-1 through their Part D plan. A diagnosis of type 2 diabetes, moderate to severe obstructive sleep apnea, or noncirrhotic MASH is reported to confer Part D GLP-1 eligibility and therefore to disqualify you from this program, even if you meet every clinical criterion. Confirm your own position with Medicare.
You need
- This pathway is available only to Medicare beneficiaries.
Worth knowing
- Requires a valid prescription from a licensed healthcare provider.
- Mounjaro is approved for type 2 diabetes, not for weight management. Coverage and program eligibility follow the diabetes indication.
- Ozempic is approved for type 2 diabetes, not for weight management. Coverage and program eligibility follow the diabetes indication.
- This program is reported to require a BMI of at least 35, or at least 27 with a weight-related comorbid condition, and to run for a bounded period through the end of 2027. It is reported to cover Foundayo, Wegovy injection and tablets, and the Zepbound KwikPen specifically rather than Zepbound vials. None of these criteria is yet confirmed against CMS.
- Medicaid GLP-1 coverage is state-by-state. A federal program reported for 2026 negotiates terms on behalf of state Medicaid agencies, but participation is voluntary and what you pay depends on your own state. There is no national Medicaid price for these medications and this site does not publish one.
- This programme is reported to cover a specific PEN presentation of this medication and NOT the single-dose vials. If you have been prescribed vials, this pathway is reported not to apply to you. Check which presentation your prescription is for before you count on it.
- Two further things are reported about this programme and neither is confirmed: that what you pay may not count toward your Part D deductible or annual out-of-pocket maximum, and that low-income subsidies may not reduce it. If either is true, a low-income beneficiary could end up worse off across a year than the monthly figure suggests. Ask Medicare.
- Two things are reported about this programme that would matter a great deal if true, and neither is confirmed: that what you pay here may not count toward your Part D deductible or your annual out-of-pocket maximum, and that low-income subsidies may not reduce it. If either holds, a low-income beneficiary could pay more across a year than the monthly figure suggests. Ask Medicare directly.
Some rules above are applied from program terms we have not yet been able to read directly. Where that is so, we apply the rule that narrows your options rather than widens them, because telling someone a discount is available when it is not is the more damaging error. How we handle unverified rules.
What is reported
The program is reported to provide a fixed low monthly cost to eligible Medicare beneficiaries, subject to a BMI threshold, with a further route in at a lower BMI where a weight-related comorbid condition is present. It is reported to cover a multi-dose pen rather than single-dose vials, and to exclude beneficiaries whose therapy is already covered under the obstructive sleep apnea indication.
What we could not confirm, and what we did about it
We could not reach CMS to confirm any of it: whether the program launched on its reported date, its actual eligibility criteria, or its actual beneficiary cost. The refusals we hit on 2026-07-30 came from our own network rather than from CMS, but the effect is the same: we have not read those pages.
So the cost renders as unverified rather than as a number. The exclusions, however, we apply anyway, because applying them is the cautious direction. If we are wrong about the sleep apnea exclusion, we have told an eligible beneficiary to check with Medicare. If we omitted it and it is real, we would have quoted a price to someone who cannot get it. Between those two errors there is no contest.
Confirm your own eligibility with Medicare directly before relying on anything here.
If you are on Medicare, the savings card is not an option
Manufacturer copay and savings cards exclude anyone enrolled in a federal healthcare program. Our tool removes that pathway entirely for Medicare and Medicaid beneficiaries rather than showing a low copay you cannot claim. What remains available is this program, standard Part D coverage where your plan covers the indication, and cash-pay direct programs.
Every figure we hold for this pathway
| Medication | Pathway | Dose or tier | Monthly | Confidence | Source type | Verified | Source |
|---|---|---|---|---|---|---|---|
| Zepbound | Medicare GLP-1 Bridge | any | Not verified | Not verified | Primary, government | 2026-07-30 | Open |
| Wegovy | Medicare GLP-1 Bridge | any | Not verified | Not verified | Primary, government | 2026-07-30 | Open |
| Wegovy tablets | Medicare GLP-1 Bridge | any | Not verified | Not verified | Primary, government | 2026-07-30 | Open |
| Foundayo | Medicare GLP-1 Bridge | any | Not verified | Not verified | Primary, government | 2026-07-30 | Open |
Compare it against everything else
A single pathway in isolation cannot tell you whether it is your cheapest option. Use the tool to rank this pathway against every other one for your medication, your insurance situation and your dose.